Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay

NACompletedINTERVENTIONAL
Enrollment

1,265

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

December 22, 2020

Study Completion Date

May 9, 2022

Conditions
Covid19
Interventions
DIAGNOSTIC_TEST

ID Now™ COVID-19 Screening Test

"Patients, meeting the eligibility criteria, are selected consecutively in the emergency room. The investigating doctor delivers the written information note, answers the patient's questions and obtains his free, informed and express consent. The patient has sufficient time to reflect to make the decision to participate in the study. His oral, free, informed and express consent will be traced in the computerized medical file on the day of its inclusion in the COVID-IDNow protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."

Trial Locations (1)

75014

Groupe Hospitalier Paris Saint-Joseph, Paris

All Listed Sponsors
lead

Fondation Hôpital Saint-Joseph

OTHER

NCT04785898 - Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay | Biotech Hunter | Biotech Hunter